Cargando…
Mutation signatures implicate aristolochic acid in bladder cancer development
BACKGROUND: Aristolochic acid (AA) is a natural compound found in many plants of the Aristolochia genus, and these plants are widely used in traditional medicines for numerous conditions and for weight loss. Previous work has connected AA-mutagenesis to upper-tract urothelial cell carcinomas and hep...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443665/ https://www.ncbi.nlm.nih.gov/pubmed/26015808 http://dx.doi.org/10.1186/s13073-015-0161-3 |
_version_ | 1782373035348590592 |
---|---|
author | Poon, Song Ling Huang, Mi Ni Choo, Yang McPherson, John R Yu, Willie Heng, Hong Lee Gan, Anna Myint, Swe Swe Siew, Ee Yan Ler, Lian Dee Ng, Lay Guat Weng, Wen-Hui Chuang, Cheng-Keng Yuen, John SP Pang, See-Tong Tan, Patrick Teh, Bin Tean Rozen, Steven G |
author_facet | Poon, Song Ling Huang, Mi Ni Choo, Yang McPherson, John R Yu, Willie Heng, Hong Lee Gan, Anna Myint, Swe Swe Siew, Ee Yan Ler, Lian Dee Ng, Lay Guat Weng, Wen-Hui Chuang, Cheng-Keng Yuen, John SP Pang, See-Tong Tan, Patrick Teh, Bin Tean Rozen, Steven G |
author_sort | Poon, Song Ling |
collection | PubMed |
description | BACKGROUND: Aristolochic acid (AA) is a natural compound found in many plants of the Aristolochia genus, and these plants are widely used in traditional medicines for numerous conditions and for weight loss. Previous work has connected AA-mutagenesis to upper-tract urothelial cell carcinomas and hepatocellular carcinomas. We hypothesize that AA may also contribute to bladder cancer. METHODS: Here, we investigated the involvement of AA-mutagenesis in bladder cancer by sequencing bladder tumor genomes from two patients with known exposure to AA. After detecting strong mutational signatures of AA exposure in these tumors, we exome-sequenced and analyzed an additional 11 bladder tumors and analyzed publicly available somatic mutation data from a further 336 bladder tumors. RESULTS: The somatic mutations in the bladder tumors from the two patients with known AA exposure showed overwhelming AA signatures. We also detected evidence of AA exposure in 1 out of 11 bladder tumors from Singapore and in 3 out of 99 bladder tumors from China. In addition, 1 out of 194 bladder tumors from North America showed a pattern of mutations that might have resulted from exposure to an unknown mutagen with a heretofore undescribed pattern of A > T mutations. Besides the signature of AA exposure, the bladder tumors also showed the CpG > TpG and activated-APOBEC signatures, which have been previously reported in bladder cancer. CONCLUSIONS: This study demonstrates the utility of inferring mutagenic exposures from somatic mutation spectra. Moreover, AA exposure in bladder cancer appears to be more pervasive in the East, where traditional herbal medicine is more widely used. More broadly, our results suggest that AA exposure is more extensive than previously thought both in terms of populations at risk and in terms of types of cancers involved. This appears to be an important public health issue that should be addressed by further investigation and by primary prevention through regulation and education. In addition to opportunities for primary prevention, knowledge of AA exposure would provide opportunities for secondary prevention in the form of intensified screening of patients with known or suspected AA exposure. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-015-0161-3) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-4443665 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-44436652015-05-27 Mutation signatures implicate aristolochic acid in bladder cancer development Poon, Song Ling Huang, Mi Ni Choo, Yang McPherson, John R Yu, Willie Heng, Hong Lee Gan, Anna Myint, Swe Swe Siew, Ee Yan Ler, Lian Dee Ng, Lay Guat Weng, Wen-Hui Chuang, Cheng-Keng Yuen, John SP Pang, See-Tong Tan, Patrick Teh, Bin Tean Rozen, Steven G Genome Med Research BACKGROUND: Aristolochic acid (AA) is a natural compound found in many plants of the Aristolochia genus, and these plants are widely used in traditional medicines for numerous conditions and for weight loss. Previous work has connected AA-mutagenesis to upper-tract urothelial cell carcinomas and hepatocellular carcinomas. We hypothesize that AA may also contribute to bladder cancer. METHODS: Here, we investigated the involvement of AA-mutagenesis in bladder cancer by sequencing bladder tumor genomes from two patients with known exposure to AA. After detecting strong mutational signatures of AA exposure in these tumors, we exome-sequenced and analyzed an additional 11 bladder tumors and analyzed publicly available somatic mutation data from a further 336 bladder tumors. RESULTS: The somatic mutations in the bladder tumors from the two patients with known AA exposure showed overwhelming AA signatures. We also detected evidence of AA exposure in 1 out of 11 bladder tumors from Singapore and in 3 out of 99 bladder tumors from China. In addition, 1 out of 194 bladder tumors from North America showed a pattern of mutations that might have resulted from exposure to an unknown mutagen with a heretofore undescribed pattern of A > T mutations. Besides the signature of AA exposure, the bladder tumors also showed the CpG > TpG and activated-APOBEC signatures, which have been previously reported in bladder cancer. CONCLUSIONS: This study demonstrates the utility of inferring mutagenic exposures from somatic mutation spectra. Moreover, AA exposure in bladder cancer appears to be more pervasive in the East, where traditional herbal medicine is more widely used. More broadly, our results suggest that AA exposure is more extensive than previously thought both in terms of populations at risk and in terms of types of cancers involved. This appears to be an important public health issue that should be addressed by further investigation and by primary prevention through regulation and education. In addition to opportunities for primary prevention, knowledge of AA exposure would provide opportunities for secondary prevention in the form of intensified screening of patients with known or suspected AA exposure. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (doi:10.1186/s13073-015-0161-3) contains supplementary material, which is available to authorized users. BioMed Central 2015-04-28 /pmc/articles/PMC4443665/ /pubmed/26015808 http://dx.doi.org/10.1186/s13073-015-0161-3 Text en © Poon et al.; licensee BioMed Central. 2015 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Poon, Song Ling Huang, Mi Ni Choo, Yang McPherson, John R Yu, Willie Heng, Hong Lee Gan, Anna Myint, Swe Swe Siew, Ee Yan Ler, Lian Dee Ng, Lay Guat Weng, Wen-Hui Chuang, Cheng-Keng Yuen, John SP Pang, See-Tong Tan, Patrick Teh, Bin Tean Rozen, Steven G Mutation signatures implicate aristolochic acid in bladder cancer development |
title | Mutation signatures implicate aristolochic acid in bladder cancer development |
title_full | Mutation signatures implicate aristolochic acid in bladder cancer development |
title_fullStr | Mutation signatures implicate aristolochic acid in bladder cancer development |
title_full_unstemmed | Mutation signatures implicate aristolochic acid in bladder cancer development |
title_short | Mutation signatures implicate aristolochic acid in bladder cancer development |
title_sort | mutation signatures implicate aristolochic acid in bladder cancer development |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4443665/ https://www.ncbi.nlm.nih.gov/pubmed/26015808 http://dx.doi.org/10.1186/s13073-015-0161-3 |
work_keys_str_mv | AT poonsongling mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT huangmini mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT chooyang mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT mcphersonjohnr mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT yuwillie mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT henghonglee mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT gananna mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT myintsweswe mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT sieweeyan mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT lerliandee mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT nglayguat mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT wengwenhui mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT chuangchengkeng mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT yuenjohnsp mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT pangseetong mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT tanpatrick mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT tehbintean mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment AT rozensteveng mutationsignaturesimplicatearistolochicacidinbladdercancerdevelopment |